AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit margin of ...

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...

AbbVie and Neomorph are set to enter a partnership and option-to-license agreement to develop molecular glue degraders.

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceuticals and wellness company, today announced ...

The National Medical Commission has launched an investigation into doctors whose foreign trips, funded by AbbVie Healthcare, ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

The National Medical Commission (NMC) has started its probe against 30 doctors who allegedly took pharma freebies in the form ...

Investors need to pay close attention to AbbVie (ABBV) stock based on the movements in the options market lately.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

We recently published a list of the 12 Best Stocks to Buy in 2025 for Beginners. In this article, we are going to take a look ...

From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024 ...